Reviva pharmaceuticals announces pricing of $5.0 million underwritten offering priced at-the-market under nasdaq rules

Cupertino, calif., aug. 21, 2024 (globe newswire) -- reviva pharmaceuticals holdings, inc. (nasdaq: rvph) (“reviva” or the “company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (cns), inflammatory and cardiometabolic diseases, today announced the pricing of an underwritten offering of 4,761,905 shares of the company's common stock (or pre-funded warrants in lieu thereof) and investor warrants to purchase up to 4,761,905 shares of common stock. the combined offering price of each share of common stock and accompanying warrant sold in the offering (including the pricing for the warrant repricing described below) will be equal to $1.05, priced at-the-market under the nasdaq rules. the combined offering price of each pre-funded warrant and accompanying warrant sold in the offering will be equal to $1.0499. the warrants have an exercise price of $0.7964 per share, will be immediately exercisable and will expire five years following the date of issuance. the pre-funded warrants have an exercise price of $0.0001 per share, will be immediately exercisable and may be exercised at any time after their original issuance. the offering is expected to close on or about august 22, 2024, subject to customary closing conditions.
RVPH Ratings Summary
RVPH Quant Ranking